First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment.

CONCLUSION: Deflexifol is safer and effective in bolus and infusion schedules at higher doses than that permitted by separate infusion of 5-FU and LV. A phase II study evaluating Deflexifol is planned. PMID: 30843362 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30843362?dopt=Abstract

Source: Clinical Colorectal Cancer - March 5, 2019 Category: Cancer & Oncology Authors: Clingan PR, Ackland SP, Brungs D, de Souza P, Aghmesheh M, Garg MB, Ranson RD, Parker S, Jokela R, Ranson M Tags: Asia Pac J Clin Oncol Source Type: research